Targeted agents recently approved by the FDA for the treatment of AML. ADC, antibody-drug conjugate; AML-MRC, acute myeloid leukemia with myelodysplasia-related changes; HDAC, high-dose cytarabine; HMA, hypomethylating agent; LDAC, low-dose cytarabine.